Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 6 completed trials

    Completion Rate
    100%(6/6)
    Active Trials
    0(0%)
    Results Posted
    50%(3 trials)

    Phase Distribution

    Phase 1/2
    2
    33%
    Phase 1
    4
    67%

    Phase Distribution

    4

    Early Stage

    2

    Mid Stage

    0

    Late Stage

    Phase Distribution6 total trials
    Phase 1Safety & dosage
    4(66.7%)
    Phase 1/2Combined phases
    2(33.3%)

    Highest Phase Reached

    Phase 1/2

    Trial Status & Enrollment

    Completion Rate

    100.0%

    6 of 6 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    6

    all time

    Status Distribution
    Completed(6)

    Detailed Status

    Completed6

    Development Timeline

    Analytics

    Development Status

    Total Trials
    6
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 1/2

    Trials by Phase

    Phase 14 (66.7%)
    Phase 1/22 (33.3%)

    Trials by Status

    completed6100%

    Recent Activity

    0 active trials
    Showing 5 of 6
    completedphase_1

    A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old

    NCT06944717
    completedphase_1

    A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants

    NCT07254728
    completedphase_1_2

    Norovirus Challenge Study

    NCT05212168
    completedphase_1

    A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers

    NCT05213728
    completedphase_1_2

    Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines

    NCT04875676
    View all 6 trials

    Clinical Trials (6)

    Showing 6 of 6 trials
    NCT06944717Phase 1

    A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old

    Completed
    NCT07254728Phase 1

    A Study to Evaluate Vaxart's Oral Bivalent GI.1/GII.4 Norovirus Vaccine in Healthy Lactating Females and Their Nursing Infants

    Completed
    NCT05212168Phase 1/2

    Norovirus Challenge Study

    Completed
    NCT05213728Phase 1

    A Phase 1, Open-label, Safety and Immunogenicity Study of an Oral Multi-dose Administration Regimen With an Adenoviral-vector Based Tablet Norovirus Vaccine (VXA-G1.1-NN) Administered to Healthy Adult Volunteers

    Completed
    NCT04875676Phase 1/2

    Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines

    Completed
    NCT03897309Phase 1

    Safety & Immunogenicity Study of Ad5 Based Oral Norovirus Vaccines

    Completed

    All 6 trials loaded

    Drug Details

    Intervention Type
    Biological
    Total Trials
    6